Patents Assigned to The Mclean Hospital Corporation
  • Patent number: 9750768
    Abstract: Provided are methods of isolating a novel cell population of midbrain dopaminergic neuronal progenitor cells derived from stem cells using a novel combination markers. The cell population may be used for cell therapies for the treatment of Parkinson's disease and as substrates in pharmacological assays.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: September 5, 2017
    Assignee: THE MCLEAN HOSPITAL CORPORATION
    Inventors: Kwang-Soo Kim, Sangmi Chung
  • Patent number: 9737562
    Abstract: The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (PTSD) in subjects, e.g., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce a symptom of the anxiety disorder in the subject.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: August 22, 2017
    Assignee: THE MCLEAN HOSPITAL CORPORATION
    Inventors: Edward G. Meloni, Marc J. Kaufman
  • Patent number: 9737726
    Abstract: A magnetic coil system featuring a multi-layer structure (312a, 312b), a spherical shape, or both allows for efficient generation of a gradient magnetic field that induces an electric field in air in a region proximate to the coil. By subjecting at least a portion of a person's brain to the induced electric field various psychiatric disorders can be treated.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: August 22, 2017
    Assignee: The Mclean Hospital Corporation
    Inventor: Michael Rohan
  • Publication number: 20170209441
    Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegenerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.
    Type: Application
    Filed: January 12, 2017
    Publication date: July 27, 2017
    Applicants: UNIVERSITY OF DELHI, THE MCLEAN HOSPITAL CORPORATION
    Inventors: Diwan S. RAWAT, Sunny MANOHAR, Ummadisetty Chinna RAJESH, Deepak KUMAR, Anuj THAKUR, Mohit TRIPATHI, Panyala Linga REDDY, Shamseer Kulangara KANDI, Satyapavan VARDHINENI, Kwang-Soo KIM, Chun-Hyung KIM
  • Patent number: 9662472
    Abstract: A system for convection enhanced delivery of therapeutic comprises one or more flexible, biocompatible microcatheters that are directed to a target location to deliver a therapeutic agent. The microcatheter is releasably coupled to a guide tube and directed to the desired location. The microcatheters are small and flexible in order to reach the target areas, minimize trauma at the injection site, and minimize reflux of the injectable therapeutic.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: May 30, 2017
    Assignee: THE MCLEAN HOSPITAL CORPORATION
    Inventor: Miles G. Cunningham
  • Patent number: 9567316
    Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 14, 2017
    Assignees: THE MCLEAN HOSPITAL CORPORATION, UNIVERSITY OF DELHI
    Inventors: Diwan S. Rawat, Sunny Manohar, Ummadisetty Chinna Rajesh, Deepak Kumar, Anuj Thakur, Mohit Tripathi, Panyala Linga Reddy, Shamseer Kulangara Kandi, Satyapavan Vardhineni, Kwang-Soo Kim, Chun-Hyung Kim
  • Patent number: 9517279
    Abstract: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: December 13, 2016
    Assignee: The McLean Hospital Corporation
    Inventors: John L. Neumeyer, Yu-Gui Si, Anna W. Sromek
  • Publication number: 20160287100
    Abstract: A system and method for analyzing blood flow in a subject's brain is provided. In some aspects, the method includes analyzing fMRI data to identify signals related to blood flow, and selecting a zero time lag seed regressor using the identified signals. The method also includes correlating the selected seed regressor to identify a subset of the fMRI data that correlates with the seed regressor and is offset in time, combining the subset of the data to determine a time-delayed regressor, and performing repetitions to obtain a number of time-delayed regressors, where for each repetition, the seed regressor is adjusted using a previous time-delayed regressor. The method further includes analyzing the data using the time-delayed regressors to determine blood delivery from vessels across the brain, and generating a report. In some aspects, a second recursive procedure may be performed using an optimized seed regressor obtained from a first recursive procedure.
    Type: Application
    Filed: November 7, 2014
    Publication date: October 6, 2016
    Applicant: MCLEAN HOSPITAL CORPORATION
    Inventors: Yunjie Tong, Blaise B. FREDERICK
  • Publication number: 20160272940
    Abstract: Enhanced methods for the generation of medial ganglionic eminence (MGE) cells from pluripotent stem cells are provided that involve an additional step of contacting the cells with an activator of FGF8 signaling while differentiating Pax6? cells progenitor cells into MGE cells with an activator of sonic hedgehog, and optionally a Wnt inhibitor. The activator of FGF8 signaling shifts the differentiation of the population of cells to NKX2.1+MGE cells, rather than to CopuTFII+ caudal ganglionic eminence (CGE) cells. Methods for reatment of neurological disorders, such as epilepsy, by transplant of MGE cells, or GABAergic interneurons derived from human pluripotent stem cells, into a subject in need of treatment are also provided. Human pluripotent stem cell derived MGE cells when transplanted successfully suppress spontaneous seizures, e.g. in epilepsy.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 22, 2016
    Applicant: THE MCLEAN HOSPITAL CORPORATION
    Inventor: Sangmi CHUNG
  • Publication number: 20160095887
    Abstract: The inventions disclosed herein are based on the identification of novel cell populations derived from human embryonic stem cells and other pluripotent cells. The inventive cell populations may be used for cell therapies for the treatment of various neurological diseases and as substrates in pharmacological assays.
    Type: Application
    Filed: December 15, 2015
    Publication date: April 7, 2016
    Applicant: THE MCLEAN HOSPITAL CORPORATION
    Inventors: Ole Isacson, Jan Pruszak
  • Patent number: 9249389
    Abstract: The inventions disclosed herein are based on the identification of novel cell populations derived from human embryonic stem cells and other pluripotent cells. The inventive cell populations may be used for cell therapies for the treatment of various neurological diseases and as substrates in pharmacological assays.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: February 2, 2016
    Assignee: THE MCLEAN HOSPITAL CORPORATION
    Inventors: Ole Isacson, Jan Pruszak
  • Publication number: 20150306136
    Abstract: The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (PTSD) in subjects, e.g., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce a symptom of the anxiety disorder in the subject.
    Type: Application
    Filed: December 10, 2013
    Publication date: October 29, 2015
    Applicant: THE MCLEAN HOSPITAL CORPORATION
    Inventors: Edward G. MELONI, Marc J. KAUFMAN
  • Publication number: 20150250825
    Abstract: The present invention provides populations of neural cells derived from pluripotent cells, and methods for making and using the same. Disclosed herein are methods for generating dopaminergic neurons in vitro using a combination of agents that cause differentiation of the pluripotent cells into dopaminergic neurons. Also disclosed are methods for treating a neurodegenerative disease in a patient by generating dopaminergic neurons in vitro, and transplanting them into the brain of the patient, such that the dopaminergic neurons are sufficient to reduce or eliminate the symptoms of the neurodegenerative disease.
    Type: Application
    Filed: May 21, 2015
    Publication date: September 10, 2015
    Applicant: THE MCLEAN HOSPITAL CORPORATION
    Inventors: Oliver Cooper, Ole Isacson
  • Patent number: 9050032
    Abstract: The invention features methods and systems to monitor changes in the magnitude of attentional disturbance and the magnitude of motor activity disturbance in a subject. The invention also features methods and systems for determining a subject's degree of concordance with individuals having an attentional disorder versus individuals not having an attentional disorder. The methods and systems of the invention can enable clinicians and consumers to ascertain both the severity of an attentional disorder as well as how much an individual changes over time, or with therapy.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: June 9, 2015
    Assignee: The McLean Hospital Corporation
    Inventor: Martin Teicher
  • Patent number: 9005142
    Abstract: The invention features methods and systems for the diagnosis of ADHD and related disorders. The methods and systems of the invention can also be used to ascertain how much benefit an individual would derive from a particular therapy.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: April 14, 2015
    Assignee: The McLean Hospital Corporation
    Inventors: Martin H. Teicher, Kyoko Ohashi
  • Publication number: 20150023930
    Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 22, 2015
    Applicant: The McLean Hospital Corporation
    Inventors: Diwan S. Rawat, Sunny Manohar, Ummadisetty Chinna Rajesh, Deepak Kumar, Anuj Thakur, Mohit Tripathi, Panyala Linga Reddy, Shamseer Kulangara Kandi, Satyapavan Vardhineni, Kwang-Soo Kim, Chun-Hyung Kim
  • Publication number: 20140243781
    Abstract: A system for convection enhanced delivery of therapeutic comprises one or more flexible, biocompatible microcatheters that are directed to a target location to deliver a therapeutic agent. The microcatheter is releasably coupled to a guide tube and directed to the desired location. The microcatheters are small and flexible in order to reach the target areas, minimize trauma at the injection site, and minimize reflux of the injectable therapeutic.
    Type: Application
    Filed: May 5, 2014
    Publication date: August 28, 2014
    Applicant: The McLean Hospital Corporation
    Inventor: Miles G. Cunningham
  • Publication number: 20140199274
    Abstract: Provided are methods of isolating a novel cell population of midbrain dopaminergic neuronal progenitor cells derived from stem cells using a novel combination markers. The cell population may be used for cell therapies for the treatment of Parkinson's disease and as substrates in pharmacological assays.
    Type: Application
    Filed: May 18, 2012
    Publication date: July 17, 2014
    Applicant: THE MCLEAN HOSPITAL CORPORATION
    Inventors: Kwang-Soo Kim, Sangmi Chung
  • Patent number: 8715240
    Abstract: A system for convection enhanced delivery of therapeutic comprises one or more flexible, biocompatible microcatheters that are directed to a target location to deliver a therapeutic agent. The microcatheter is releasably coupled to a guide tube and directed to the desired location. The microcatheters are small and flexible in order to reach the target areas, minimize trauma at the injection site, and minimize reflux of the injectable therapeutic.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: May 6, 2014
    Assignee: The McLean Hospital Corporation
    Inventor: Miles G. Cunningham
  • Publication number: 20140087464
    Abstract: The inventions disclosed herein are based on the identification of novel cell populations derived from human embryonic stem cells and other pluripotent cells. The inventive cell populations may be used for cell therapies for the treatment of various neurological diseases and as substrates in pharmacological assays.
    Type: Application
    Filed: September 26, 2013
    Publication date: March 27, 2014
    Applicant: THE MCLEAN HOSPITAL CORPORATION
    Inventors: Ole Isacson, Jan Pruszak